Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission.

PubWeight™: 7.13‹?› | Rank: Top 1%

🔗 View Article (PMID 14730597)

Published in Arthritis Rheum on January 01, 2004

Authors

Esmeralda T H Molenaar1, Alexandre E Voskuyl, Huib J Dinant, P Dick Bezemer, Maarten Boers, Ben A C Dijkmans

Author Affiliations

1: VU University Medical Center, Amsterdam, The Netherlands.

Articles citing this

Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03

The synovium in rheumatoid arthritis: evidence for (at least) two pathologies. Arthritis Rheum (2004) 3.71

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis (2015) 2.53

Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol (2012) 2.28

Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis (2005) 1.85

Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis (2015) 1.73

Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis (2007) 1.73

Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis (2006) 1.42

The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol (2013) 1.24

Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther (2012) 1.22

Osteoporosis in inflammatory joint diseases. Osteoporos Int (2010) 1.21

The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis (2012) 1.20

Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Ann Rheum Dis (2013) 1.18

Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther (2011) 1.17

Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis (2006) 1.16

Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) (2010) 1.14

Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs. Arthritis Res Ther (2006) 1.11

The arthritis severity locus Cia5d is a novel genetic regulator of the invasive properties of synovial fibroblasts. Arthritis Rheum (2008) 1.06

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis (2014) 1.05

Remission by composite scores in rheumatoid arthritis: are ankles and feet important? Arthritis Res Ther (2007) 1.05

Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford) (2011) 1.03

Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop. J Rheumatol (2014) 1.00

An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford) (2013) 0.99

Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis (2008) 0.99

Time to achieve remission determines time to be in remission. Arthritis Res Ther (2010) 0.97

What magnetic resonance imaging has told us about the pathogenesis of rheumatoid arthritis--the first 50 years. Arthritis Res Ther (2008) 0.95

Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity. Arthritis Res Ther (2006) 0.91

Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study. Rheumatology (Oxford) (2011) 0.90

A case-study in the clinical epidemiology of psoriatic arthritis: multistate models and causal arguments. J R Stat Soc Ser C Appl Stat (2011) 0.90

Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis. BMC Musculoskelet Disord (2011) 0.89

Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int (2014) 0.88

Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go? Arthritis Res Ther (2007) 0.86

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. RMD Open (2016) 0.85

Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Res Ther (2016) 0.84

Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate. Arthritis Res Ther (2013) 0.84

Remission in rheumatoid arthritis. Curr Rheumatol Rep (2010) 0.84

Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys? Arthritis Res Ther (2015) 0.83

Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) (2011) 0.83

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis (2015) 0.83

Prediction of erosion progression using ultrasound in established rheumatoid arthritis: a 2-year follow-up study. Skeletal Radiol (2009) 0.82

Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther (2016) 0.80

Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study. BMC Musculoskelet Disord (2011) 0.80

Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Res Ther (2010) 0.80

The relation of hand functions with radiological damage and disease activity in rheumatoid arthritis. Rheumatol Int (2007) 0.79

Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study. Rheumatol Int (2005) 0.79

Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. Arthritis Res Ther (2015) 0.79

Ultrasound of the hand is sufficient to detect subclinical inflammation in rheumatoid arthritis remission: a post hoc longitudinal study. Arthritis Res Ther (2017) 0.77

Is hand bone mineral density a marker for hand function in patients with established rheumatoid arthritis? The correlation among bone mineral density of the hand, radiological findings and hand function. Clin Rheumatol (2013) 0.77

Structural integrity versus radiographic progression in rheumatoid arthritis. RMD Open (2015) 0.77

Rationale of using different biological therapies in rheumatoid arthritis. Arthritis Res Ther (2010) 0.77

Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis. RMD Open (2016) 0.76

A window on disease pathogenesis and potential therapeutic strategies: molecular imaging for arthritis. Arthritis Res Ther (2011) 0.76

Quantitative MR characterization of disease activity in the knee in children with juvenile idiopathic arthritis: a longitudinal pilot study. Pediatr Radiol (2007) 0.76

Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan. PLoS One (2017) 0.76

Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging: preliminary findings. Eur Radiol (2009) 0.75

Preventing Collateral Damage in Crohn's Disease: The Lémann Index. J Crohns Colitis (2016) 0.75

Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy. Arthritis Care Res (Hoboken) (2015) 0.75

The Role of Power Doppler Ultrasonography as Disease Activity Marker in Rheumatoid Arthritis. Dis Markers (2015) 0.75

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis. RMD Open (2016) 0.75

Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets. Arthritis Res Ther (2017) 0.75

Registration-Based Morphometry for Shape Analysis of the Bones of the Human Wrist. IEEE Trans Med Imaging (2016) 0.75

Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS One (2016) 0.75

RANK-Independent Osteoclast Formation and Bone Erosion in Inflammatory Arthritis. Arthritis Rheumatol (2016) 0.75

Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatol (2009) 0.75

Designation of a novel DKK1 multiepitope DNA vaccine and inhibition of bone loss in collagen-induced arthritic mice. Biomed Res Int (2015) 0.75

Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis? Ther Adv Musculoskelet Dis (2010) 0.75

Radiologic progression and clinical remission in rheumatoid arthritis: comment on the article by Molenaar et al. Arthritis Rheum (2004) 0.75

Relationship of radiographic progression to the pathogenic mechanism of rheumatoid arthritis: comment on the article by Molenaar et al. Arthritis Rheum (2004) 0.75

Should the definition of clinical remission of rheumatoid arthritis be revised? Comment on the article by Molenaar et al. Arthritis Rheum (2004) 0.75

Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort. Clin Rheumatol (2014) 0.75

The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort. Clin Rheumatol (2014) 0.75

Thymosin β4 in rheumatoid arthritis: Friend or foe. Biomed Rep (2017) 0.75

Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: Which joints and tendons should be assessed to predict unstable remission? Rheumatol Int (2015) 0.75

The discrepancy between clinical and ultrasonographic remission in rheumatoid arthritis is not related to therapy or autoantibody status. Rheumatol Int (2011) 0.75

A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis. Rheumatol Int (2017) 0.75

A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure. Arthritis Rheumatol (2016) 0.75

The association between serious infection and disease outcome in patients with rheumatoid arthritis. Clin Rheumatol (2015) 0.75

Articles by these authors

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol (2007) 13.46

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004) 7.79

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28

AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol (2009) 6.00

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum (2002) 5.57

Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med (2007) 5.05

Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol (2002) 4.19

American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med (2006) 3.80

Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet (2002) 3.67

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51

OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials (2007) 3.29

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.26

Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet (2003) 3.22

The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum (2004) 2.99

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA (2011) 2.73

External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One (2007) 2.70

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis (2007) 2.67

Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61

The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol (2004) 2.56

Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum (2009) 2.55

Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol (2002) 2.42

Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther (2006) 2.28

Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2009) 2.24

Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol (2003) 2.20

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2008) 2.17

Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis (2011) 2.11

Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol (2006) 2.01

Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum (2005) 2.01

Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum (2006) 2.00

Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum (2004) 1.94

Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum (2003) 1.92

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum (2002) 1.91

Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum (2002) 1.86

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis (2010) 1.81

Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed? Ann Intern Med (2009) 1.81

Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80

Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. Arthritis Rheum (2006) 1.79

Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med (2012) 1.78

Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med (2005) 1.77

A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol (2013) 1.77

Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum (2009) 1.77

Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis (2007) 1.77

Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol (2008) 1.75

Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. J Rheumatol (2007) 1.74

Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol (2005) 1.70

Content validity of patient-reported outcome measures: perspectives from a PROMIS meeting. Qual Life Res (2011) 1.68

Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach. Qual Life Res (2006) 1.68

The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum (2011) 1.63

Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol (2002) 1.63

Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis (2011) 1.62

A multicentre study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy assessment. Rheumatology (Oxford) (2011) 1.57

Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum (2003) 1.56

Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum (2002) 1.55

Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis (2007) 1.55

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.50

Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med (2002) 1.48

The influence of methodologic quality on the conclusion of a landmark meta-analysis on thrombolytic therapy. Int J Technol Assess Health Care (2002) 1.48

Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum (2012) 1.48

Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials (2013) 1.47

Chemoreduction for retinoblastoma. Arch Ophthalmol (2003) 1.46

The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. Arthritis Rheum (2010) 1.45

Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy (2012) 1.41

Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol (2003) 1.41

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis (2011) 1.40

Percutaneous coronary intervention with off-site cardiac surgical backup. Am J Cardiol (2008) 1.40

Different type of carotid arterial wall remodeling in rheumatoid arthritis compared with healthy subjects: a case-control study. J Rheumatol (2012) 1.40

Core outcome domains for clinical trials in non-specific low back pain. Eur Spine J (2015) 1.40

The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol (2003) 1.39

Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum (2011) 1.39

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis (2010) 1.38

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis (2007) 1.37

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol (2007) 1.35

Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol (2007) 1.33

The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis (2010) 1.31

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis (2012) 1.31

Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis (2009) 1.29

Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission. J Rheumatol (2002) 1.29

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther (2012) 1.29

Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol (2005) 1.28

Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Rheum (2003) 1.28

Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum (2010) 1.28

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum (2010) 1.27

Burden of caregiving: evidence of objective burden, subjective burden, and quality of life impacts on informal caregivers of patients with rheumatoid arthritis. Arthritis Rheum (2004) 1.26